Press Releases May 7, 2026 05:05 PM

Strata Critical Medical Announces Expiration of Warrants

Strata Critical Medical Announces Expiration of Public and Private Warrants per Original Terms

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
SRTA

Strata Critical Medical, Inc. announced that both its Public Warrants (SRTAW) and Private Placement Warrants expired as scheduled on May 7, 2026, at 5:00 p.m. Eastern Time. The expiration occurred in accordance with the original terms set for these warrants.

Strata Critical Medical Announces Expiration of Warrants
SRTA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Both Public Warrants (SRTAW) and Private Placement Warrants expired as originally scheduled on May 7, 2026.
  • Strata Critical Medical provides critical logistics and medical services for the U.S. healthcare industry, focusing on organ transplant support.
  • The company operates one of the largest air transport and surgical service networks for transplant hospitals and organ procurement organizations in the U.S.

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Strata Critical Medical, Inc. (Nasdaq: SRTA, “Strata” or the “Company”), announced that its warrants, both the Public Warrants (Nasdaq: SRTAW) and the Private Placement Warrants, expired in accordance with their original terms at 5:00 p.m. Eastern Time today May 7, 2026.

About Strata Critical Medical, Inc.

Strata is a time-critical logistics and medical services provider to the U.S. healthcare industry. We operate one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated “one call” solution for donor organ recovery.

Strata’s core services include air and ground logistics, surgical organ recovery, organ placement and normothermic regional perfusion for the transplant industry, as well as perfusion staffing and equipment solutions for cardiovascular surgery centers, offered under the Trinity Medical Solutions and Keystone Perfusion brands.

For more information, visit www.srta.com.

Contacts

Mathew Schneider
investors@srta.com


Risks

  • Expiration of warrants may limit the company’s ability to raise capital through warrant exercises in the near term, possibly impacting liquidity.
  • Dependence on the U.S. healthcare sector and transplant demand exposes the company to regulatory and healthcare funding uncertainties.
  • Operational risks related to air transport and surgical services, such as logistical challenges or disruptions, could impact service delivery.

More from Press Releases

Gilat Awarded Over $32 Million for Multi-Band DKET Systems Supporting U.S. Defense Network Resilience Sep 9, 2026 Bilibili Inc. Announces Completion of US$500 Million Marketed Convertible Senior Notes Offering, Concurrent Equity Placement and Concurrent Delta Repurchase Sep 9, 2026 Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation Sep 9, 2026 OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026 Sep 9, 2026 Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment Sep 9, 2026